Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake.To assess the all-oral 3 direct-acting antiviral (3D)...

詳細記述

保存先:
書誌詳細
主要な著者: Mark Sulkowski, Joseph J. Eron, David Wyles, Roger Trinh, Jay Lalezari, Chia Wang, Jihad Slim, Laveeza Bhatti, Joseph Gathe, Peter Ruane, Richard Elion, Fritz Bredeek, Robert T. Brennan, Gary Blick, Amit Khatri, Krystal Gibbons, Yiran Hu, Linda Fredrick, Gretja Schnell, Edward Tam, Rakesh Tripathi, Barbara Da Silva‐Tillmann, Barbara McGovern, Andrew Campbell, Thomas Podsadecki
フォーマット: Artigo
言語:英語
出版事項: 2015
オンライン･アクセス:https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

インターネット

https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf

類似資料